CLINICAL PHARMACOKINETICS OF RIFAMPICIN IN PATIENTS WITH TUBERCULOSIS AND TYPE 2 DIABETES MELLITUS: ASSOCIATION WITH BIOCHEMICAL AND IMMUNOLOGICAL PARAMETERS

Medellín-Garibay SE¹, Cortez-Espinosa N¹, Milán-Segovia RC¹, Magaña-Aquino M², Vargas-Morales JM¹, González-Amaro R³, Portales-Pérez DP¹, Romano-Moreno S¹*

¹Facultad de Ciencias Químicas, Universidad Autónoma de San Luis Potosí, San Luis Potosí, México; ²Hospital Central “Dr. Ignacio Morones Prieto”, San Luis Potosí, México; ³Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, México.

Running title: Effect of Diabetes on Rifampicin Pharmacokinetics

Keywords: Tuberculosis, type 2 diabetes mellitus, immune parameters, pharmacokinetics, rifampicin

#Address correspondence to: Silvia Romano Moreno, srm@uaslp.mx
ABSTRACT

Tuberculosis (TB) remains a major public health issue due to the increasing incidence of type 2 diabetes mellitus (T2DM), which exacerbates the clinical course of TB and increases the risk of poor long-term outcomes. The aim of this study was to characterize the pharmacokinetics of rifampicin (RIF) and its relationship with biochemical and immunological parameters in patients with TB and T2DM. The biochemical and immunological parameters were assessed on the same day the pharmacokinetic evaluation of RIF was performed. Factors related to the metabolic syndrome that is characteristic of T2DM patients were not detected in the TB–T2DM group (where predominant malnutrition was present) or in the TB group. Percentages of CD8+ T lymphocytes and NK cells were diminished in the TB and TB–T2DM patients, who had high TNF-α and low IL-17 levels compared to healthy volunteers. Delayed RIF absorption was observed in the TB and TB–T2DM patients; absorption was poor and slower in the latter group due to poor glycemic control. RIF clearance was also slower in the diabetic patients, thereby prolonging the mean residence time of RIF. There was a significant association between the influence of diabetes, glycemic control and increased TNF-α serum concentration and RIF pharmacokinetics in the TB-T2DM patients. These altered metabolic and immune conditions may be factors in anti-TB therapy management when TB and T2DM are concurrently present.
Tuberculosis (TB) is an infectious disease caused by the Mycobacterium tuberculosis complex (Mtbc) and remains a major cause of morbidity and mortality in developing countries. In 2013, an estimated 9 million people developed the disease, resulting in 1.5 million deaths (1). One-third of the population is infected with Mtbc, but only 5–10% develop active TB disease. The risk is increased by the presence of risk factors such as HIV, diabetes mellitus (DM), malnutrition and other environmental factors (2). The increasing incidence of type 2 diabetes mellitus (T2DM) raises the risk of developing active TB in high-burden regions two- to eight-fold over the baseline, especially in individuals with poor glycemic control (3-5). Moreover, an exacerbated TB clinical course and an increased risk of poor long-term outcomes have been reported for T2DM patients (6).

The cure rate reported after the directly observed treatment short-course (DOTS) for TB was greater than 85%, with less than 5% of subjects relapsing (1). However, Jiménez-Corona examined 1262 TB patients from southern Mexico and found that the prevalence of T2DM was 29.63. T2DM was associated with more severe clinical manifestations (adjusted odds ratio (OR) = 1.80), delayed sputum conversion (OR = 1.51) and a higher probability of treatment failure (OR = 2.93) (9). Differences in the pharmacokinetics (PK) of Rifampicin (RIF), the most important anti-TB concentration-dependent drug, may contribute to an increased risk of TB treatment failure for diabetic patients (10-14). Additionally, the Jiménez-Corona’s study, showed...
that TB recurrence in diabetic individuals compared with non-diabetic individuals was caused by Mtb of the same genotype in 81% of cases, indicating a predominance of relapse over exogenous reinfection (9). The molecular basis for this susceptibility to TB in diabetic patients is unclear. One possibility is a compromised immune response in diabetic patients that facilitates either primary progressive tuberculosis or the reactivation of latent tuberculosis infection. Chronic hyperglycemia is associated with dysfunctional immunity to Mtb in T2DM patients (15) and hence is likely to reduce the efficacy of anti-mycobacterial treatment.

The immune response against Mtb is complex, heterogeneous and has not been completely characterized. CD4+ T lymphocytes in combination with cytokines such as IFN-γ and TNF-α are fundamental for the control of the infection (7). However, active TB in patients with T2DM is characterized by an increased but delayed adaptive response involving CD4+ T-cells and cytokines (8). Other types of cells, such as CD8+ T lymphocytes, monocytes and natural killer (NK) cells, are also involved in anti-Mtb immunity, but their role in T2DM susceptibility to TB infection is unclear (7, 8).

Biochemical and immunological parameters reflect the pathophysiological status of TB patients with or without T2DM, and the PK of a drug may be modified according to a patient’s condition. Therefore, the aim of this study was to characterize the PK of RIF with suitable time point sampling after a single standard dose. Furthermore, we evaluated biochemical and immunological parameters in TB patients with or without T2DM and examined their correlation with drug disposition.
MATERIALS AND METHODS

Ethics statement. The study was conducted according to the principles expressed in the Declaration of Helsinki and was approved by the Research Ethics Committee of Health Services of San Luis Potosi, Mexico. All patients and volunteers provided written informed consent for the collection of samples and subsequent analysis.

Patients and healthy volunteers. A longitudinal prospective study was performed in healthy volunteers, patients with a diagnosis of T2DM, TB patients and patients with TB and T2DM. The age of the participants ranged from 18 to 65 years. Patients were included consecutively and matched by gender. Patients were recruited from Infectology and Endocrinology Services in the Hospital Central “Dr. Ignacio Morones Prieto” in San Luis Potosi, Mexico. TB was diagnosed based on the clinical presentation and was confirmed by microscopic detection of acid-fast bacilli or microbiologic culture. T2DM diagnosis was based on standard guidelines: fasting glycemia > 126 mg/dL and hemoglobin A1c (HbA1c) > 6.5% (16). Screenings for TB or T2DM were performed to sort each patient into the corresponding study group. For healthy volunteers, renal and hepatic function tests, urinalysis and a chest X-ray were performed at the time of the study. Pregnant women, HIV-positive patients, and patients with inflammatory disorders, microvascular and macrovascular complications, abnormal liver, renal, or thyroid function, steroid therapy and immunosuppressive medication were excluded. Blood counts and biochemical parameters, such as glycemia, HbA1c, total cholesterol, HDL cholesterol, LDL
cholesterol and triglycerides, were measured in the serum of patients and healthy volunteers after 10–12 hours of fasting.

For healthy volunteers and T2DM patients, blood samples were obtained randomly when all of the inclusion criteria were completed. For TB and T2DM-TB patients, samples were drawn on the first day of the DOTS scheme after the TB diagnosis was confirmed.

**Isolation of peripheral blood mononuclear cells.** Blood samples were obtained by venipuncture and collected in tubes with EDTA as an anticoagulant. Peripheral blood mononuclear cells (PBMC) were isolated using Ficoll-Hypaque density gradient centrifugation (Sigma Chemicals, St Louis, MO, USA). Cell viability was evaluated with trypan blue staining. Then, the cells were washed and counted in a Neubauer chamber and adjusted to $1 \times 10^6$ cells/mL in PBS.

**Flow cytometry.** PBMCs were immunostained with the mouse anti-human-CD4-fluorescein isothiocyanate (FITC), anti-human-CD8-FITC, anti-human-CD14-FITC or anti-human-CD56-FITC monoclonal antibodies (BD-Pharmigen, San Diego, CA, USA) for 20 min at 4°C. After incubation, the labeled PBMCs were washed and fixed with 1% paraformaldehyde. Cells were gated in a FACSCalibur flow cytometer with the CellQuest software (Becton Dickinson, San Jose, CA, USA). The results were presented as the percentage of positive cells relative to the blood counts and were reported as the absolute number of cells per µL.
Serum cytokine quantification. Serum was collected and frozen (<-20°C) prior to the cytokine assay. Levels of cytokines (IFN-γ, TNF-α, IL-17 and IL-10) were measured using a commercial enzyme-linked immunosorbent assay (ELISA) according to the manufacturer's instructions (R&D Systems, Minneapolis, MN, USA).

Pharmacokinetics assessment. During the first day of DOTS, the TB and TB–T2DM patients received a standard dose of RIF, isoniazid and pyrazinamide (Rifater®, Sanofi-Aventis, Mexico, D.F.) under fasting conditions with the following weight criteria: three tablets for patients <50 kg and four tablets for patients >50 kg. This formulation contained 150 mg of RIF, 75 mg of isoniazid and 400 mg of pyrazinamide per tablet. A standard low-fat diet was provided 3, 6 and 12 hours after medication intake; the patients were allowed to ingest water ad libitum (17, 18). After the drugs were taken, blood samples were collected 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 24 hours post-dose. Plasma was immediately separated and frozen at -80°C prior to analysis.

Quantification of Rifampicin in plasma. The plasma concentration of RIF was assessed using the high-performance liquid chromatography (HPLC) method that was previously described and validated (19). The HPLC Breeze System consisted of a 1525 multisolvent delivery system, a 717 Plus loop-injector, a UV/Visible 2487 detector and software (Waters Corporation, Milford, MA, USA). RIF was extracted from human plasma by adding acetonitrile (Fermont). The method was previously validated in a range from 0.1 to 20 mg/L with an accuracy of 99.7% using a USP Reference Standard.
for RIF. The inter- and intra-assay coefficients of variation (CV) were 1.41% and 8.71%, respectively. The limit of detection was 0.03 mg/L, and the limit of quantification was 0.1 mg/L (CV=3.2%). Samples measured below the assay range were assigned a value equal to the median between the lower limit of quantification and the limit of detection.

**Pharmacokinetic analysis.** Plasma concentration versus time for each volunteer was assessed using compartmental and non-compartmental approaches (WinNonlin version 6.3; Pharsight Corp., St. Louis, MO, USA). For the non-compartmental model, the maximum observed concentration (Cmax) and the time at which this occurred (Tmax) were collected directly from the pharmacokinetic profile. The area under the concentration–time curve to the last observation point (AUC₀₋₂₄₉) was calculated with the linear trapezoidal rule. The point extrapolated to infinity (AUC₀₋∞) was based on the last time estimated as AUC₀₋∞ = AUC₀₋₂₄₉ + C₂₄₉/λz, where λz was the first-order rate constant associated with the terminal (log-linear) portion of the curve estimated by the linear regression of time vs. log concentration. The mean residence time (MRT) was calculated as follows: MRT = AUMC₀₋∞/AUC₀₋∞.

One-compartment open models were performed with first order absorption and elimination with a lag time (tlag) in the absorption phase. The parameters evaluated by the compartmental model were the volume of distribution (Vd), the rate (Ka) and the half-life (t₁/₂abs) of absorption, the rate (Ke) and the half-life (t₁/₂e) of elimination,
the tlag as the time prior to the first measurable concentration, and the total body clearance (CL).

Statistical analysis. Pharmacokinetic parameters and covariates were assessed using the Kolmogorov–Smirnov test to determine the normality of the data distribution. Differences in anthropometric, biochemical, immunological and pharmacokinetic parameters between TB, TB–T2DM, and T2DM patients and healthy volunteers were assessed with a one-way analysis of variance (ANOVA) with Tukey’s post-hoc or Kruskal–Wallis with Duncan’s post-hoc test for parametric or non-parametric data, respectively. Pearson correlations were performed between continuous variables and PK parameters according to the group analyzed. All statistical evaluations were performed with GraphPad Prism V.5. P values less than 0.05 were considered statistically significant.
RESULTS

Patients and healthy volunteers. The anthropometric and biochemical characteristics of the 24 TB patients, 24 TB–T2DM patients, 24 T2DM patients and 24 healthy volunteers included in the current study are detailed in Table 1. The predominant pulmonary form was observed for 62.5% of the TB patients and 87% of the TB–T2DM patients. The diabetic TB patients were older than the non-diabetic TB patients (P< 0.001); the body mass index (BMI) and dose per kg of RIF were similar between these groups. Close to 70% of the diabetic TB patients were previously diagnosed with T2DM; the remainder of these patients were diagnosed as diabetic at the time of the study.

To confirm the diagnosis and management of T2DM in patients with or without TB, blood glucose and HbA1c levels were determined after 10–12 hours of fasting (Table 1). The percentages of diabetic patients with or without TB with poor glycemic control (HbA1c> 8%) were 60% and 47%, respectively; no differences in the average glucose and HbA1c values were found between the TB–T2DM and T2DM groups. Most of the T2DM (90%) and T2DM-TB patients (63%) were under treatment at the time of the study: 50% were treated with oral antidiabetics (metformin/glyburide) and the remainder received insulin s.c..

Most of the T2DM patients had a metabolic disorder characterized by dyslipidemia, excess body weight or obesity (P< 0.0001). In this study, BMI, total cholesterol, LDL...
and triglycerides were not altered in patients who presented with both conditions, which was a significant difference compared with the group with T2DM alone (P<0.0001). The HDL cholesterol levels were close to the lower limit in patients with TB and TB–T2DM and were significantly different compared to the healthy volunteers or T2DM patients without evidence of infection (P <0.001). Notably, none of the patients enrolled in the current study had severe liver damage, kidney failure or other complications as a result of T2DM. Furthermore, none of these patients were on medication to control lipid levels or had received antihypertensive or immunosuppressive treatment.

**Immune parameters.** To characterize the immune system statuses of the T2DM patients with TB, T-cell (CD4+ and CD8+), NK cell (CD56+) and monocyte (CD14+) populations were measured with flow cytometry. As shown in Figure 1a, the healthy controls, TB patients and TB–T2DM patients had the same total CD4+ T-cell numbers. However, CD8+ and CD56+ cells were diminished in the TB and TB–T2DM groups compared with the healthy controls (Figure 1b–c). In the T2DM group, increased numbers of both CD4+ and CD8+ T-cells were found compared with the TB and TB–T2DM groups. Conversely, no differences in the total peripheral blood monocytes were found for any group (Figure 1d).

IFN-γ is an important cytokine for the TB immune protective response (20). Multifunctional T-cells, which are producers of different cytokines, have also been reported to be associated with protective immunity toward Mtb (21). Therefore, TNF-
α, IL-10, IL-17 and IFN-γ levels were determined in the sera of the healthy controls, TB, T2DM and TB–T2DM patients. High levels of TNF-α (Figure 2a) and low levels of IL-17 (Figure 2d) were observed in the TB and TB–T2DM patients compared with the healthy controls. In contrast, the IFN-γ and IL-10 concentrations were comparable between the groups studied (Figure 2b–c).

Pharmacokinetics of Rifampicin. The RIF average plasma concentrations versus time for each of the study groups are shown in Figure 3. A wide variability in the plasma levels of the anti-TB drug was observed for up to 24 hours after the single dose was detected. The same presentation of the drug was used to eliminate differences attributable to changes in the fraction absorbed due to the effects of excipients and formulation quality (19, 22).

Table 2 shows the pharmacokinetic parameters obtained from the non-compartmental and compartmental analyses and the results of the statistical analysis. The one-compartment open model with first-order elimination and a lag in the absorption phase represented better evolution of the RIF plasma concentrations.

According to the value of Cmax, 65% of the subjects reached the reference value of RIF (8–24 mg/L); these patients were equally distributed between the TB and TB–T2DM patients. Considerable variability was observed in the RIF plasma concentrations. The time to reach Cmax (Tmax) was 2 h for the TB patients and increased to 3 h in the TB–T2DM patients (P= 0.03). Likewise, the lag obtained with the one-compartment open model was greater in the TB–T2DM patients (P= 0.04), and the absorption rate (Ka)
was decreased in the diabetic and non-diabetic TB patients compared to the healthy volunteers (P = 0.01).

A wide inter-individual variability in the area under the time–concentration curves (AUC0–24h and AUC0–∞) was found between groups. Thus, it was not possible to detect significant differences in these parameters according to the disease status. The MRT expresses the permanency of RIF in the organism based on the processes of absorption (including tlag) and elimination; this value was higher for the TB–T2DM patients (P = 0.02) compared to the other groups in this study.

The average volume of distribution (Vd) was similar between groups; however, it was significantly increased in the TB–T2DM patients (P = 0.01) when it was normalized to total body weight (Vd/TBW). In contrast, there was no difference in the rate of elimination (calculated as Ke and t1/2e) between patients. The mean value of clearance (CL), reported as a rate of 6 L/h for the TB–T2DM patients, was significantly lower compared with the non-diabetic TB patients (P = 0.04).

**Correlation between RIF’s PK and biochemical or immunological parameters.** To assess clinically relevant characteristics that might be related to RIF’s disposition, each anthropometric, biochemical and immunological parameter was correlated with the evaluated pharmacokinetic parameters. As expected, the AUC, Vd and CL of RIF were associated with the total body weight (P < 0.05) in healthy volunteers; this finding was not observed in the TB and TB-T2DM patients. In the TB–T2DM patients, clear trends were found for glycemic control (fast glycemia and HbA1c) with tlag and
Cmax. Additionally, TNF-α was related to a significant extent with the Vd/TBW of RIF (P < 0.05) (Figure 4). The remainder of the parameters remained non-significant.
DISCUSSION

The National Center for Epidemiological Surveillance and Control of Diseases (CENAVECE) in México reported that TB was associated with T2DM in a greater proportion of patients over 50 years of age (35%). The association of TB with HIV/AIDS was less prevalent (10% in the 20–40 year age range) and reached 25% in patients with moderate to severe malnutrition. This finding was corroborated by the results obtained in the present study. The BMI, which is typically used to assess excess body weight or obesity (23), was higher in the group with T2DM. This finding was not observed in patients with TB-T2DM (P <0.05). A loss of 20% of total body weight is a regular characteristic of TB patients, and this is reflected in the finding that a third of the patients had BMIs <18.49 kg/m². However, this state of malnutrition occurred in only 10% of the TB-T2DM patients.

Adverse effects of hyperglycemic conditions such as T2DM induce abnormal functions in cells of the innate and adaptive immune response, which are potentially relevant to host defense against TB (24). The CD4+ T-cells involved in the protective immune response against Mtb are key factors for the resolution of the infection, and low levels and abnormal functions of CD4+ T cells may develop into clinically evident disease. In contrast, CD8+ T-cells are generally thought to contribute to optimal immunity and protection, and a recent study demonstrated that these cells could be a better biomarker of the protective response against TB and the response to therapy than CD4+ T-cells (25, 26). The relevance of innate cells such as monocytes/macrophages...
and NK cells has been well described (8). However, no reports on T-cell subpopulations, monocytes and NK cell status have been performed in the context of RIF pharmacokinetics in TB–T2DM patients to date. Impaired host defenses in TB–T2DM patients might occur as a consequence of persistent hyperglycemia (27). Here, differences in the numbers of CD8+ and CD56+ cells in both TB and TB–T2DM patients were found compared with the control group, although the differences relative to the time evolution of T2DM in TB patients were not significant (data not shown). No significant differences in total cell numbers were observed between TB and TB–T2DM patients. These latter results are in agreement with a recent study by Kumar et al. (28), who compared T-cell frequencies in pulmonary TB patients with or without DM from a cohort in Chennai, India, and found no differences between the 2 groups in the absolute numbers of CD4+ and CD8+ T cells. However, the frequencies of subpopulations of immune cells, such as Th1, Th17, and regulatory T-cells, were different between the diabetic and non-diabetic TB groups (28). Therefore, it would be of great interest to evaluate the behavior of these cell populations throughout the course of treatment because the success or failure of the treatment outcome may be related to the restoration of immunity.

Previous studies involving patients with TB and T2DM reported significantly higher levels of IFN-γ production in response to PPD than nondiabetic TB patients (15). Stalenhoef et al. (29), detected lower IFN-γ levels in PBMCs stimulated with Mtb from TB patients with or without T2DM. These findings and the current results may appear to be contradictory because T2DM patients are more susceptible to develop active TB;
however, these patients also show alterations in the downstream signal transduction of key Th1 and innate immune response cytokines, possibly due to an increase in advanced glycation end products that can bind and modify protein functions as described by Restrepo et al. (15, 30). The current work utilized fresh serum, which could explain why differences were not found in the levels of IFN-γ observed in TB patients with or without T2DM.

The IL-10 and TNF-α concentrations were in agreement with a previous report (28). Several studies have reported that IL-17 is involved in immune protection against *Mtb*, primarily due to the function of this cytokine in attracting and activating neutrophils (31); Kumar et al. reported increased levels of this cytokine in TB–T2DM patients compared with the TB group, which was in contrast with our results (28). Other characteristics of the study population, such as genetic background, may have contributed to these discrepancies.

No differences between TB and TB–T2DM patients were found in either the total cells numbers or serum cytokine concentrations. Data from animal models indicate that the adverse impact of chronic hyperglycemia occurs on the initiation of the adaptive immune response rather than on its magnitude. However, variability between culture conditions or the populations studied has contributed to the limited knowledge regarding the biological basis of the association between TB and T2DM.

Previous studies in TB–T2DM patients reported the non-compartmental pharmacokinetics of RIF (10, 11). Due to the suitable time point sampling performed...
in the current study, a one-compartment open model with first-order elimination allowed us to characterize the absorption and elimination phases. The pharmacokinetic profiles showed a better fit by adding a tlag. Although the Cmax average was >8 mg/L (which was regarded as the lower limit of the plasma concentration expected at Tmax) (13, 32, 33), levels below this value were found in both groups of patients. This is relevant because there is evidence that RIF’s effect is a function of the concentration found in the blood (13, 14). Additionally, this concentration is expected to decrease after at least one week of treatment, when the activity of liver enzymes and transporters are changed by RIF induction (34). We found a tlag of 30 minutes in TB patients; this is the time it takes for the drug to appear in the blood. Conversely, the tlag increased to 40 minutes on average in patients with TB-T2DM (P= 0.04). This process is regulated by the efflux pump P-glycoprotein (Pgp) duodenal. Thus, saturation of the system is required to facilitate RIF’s entry into the bloodstream (22). The increase in tlag observed in patients with TB-T2DM could have a significant impact on the magnitude of the bioavailability of this antibiotic in these patients (35). This was reflected in the current study because poor glycemic control was associated with both the increase in tlag and the decrease in Cmax. Additionally, the rate of absorption (Ka) was decreased significantly in patients with TB-T2DM due to the increased tlag, and therefore the mean absorption time (t1/2a) of RIF increased up to two hours in this group of patients. RIF shows a wide pharmacokinetic variability in the absorption process in patients with TB. Population studies identified a high inter-individual variability of 66% to
93% that was attributed to the absorption process and specifically to the value of Ka
(19, 36). However, this significant variation in TB patients can be explained by a
possible reduction in the intestinal area based on the extent of malnutrition in these
patients (37). For TB-T2DM patients, another important aspect to consider is the
lower intestinal motility that has been previously reported in patients with diabetes;
this effect reduces gastric emptying, changes the pH level, and therefore delays the
absorption of some drugs (38). Furthermore the distribution process was shown to be
substantially diminished in patients with TB, which was determined by comparing the
Vd/TBW in patients with both pathologies.

Several studies in patients with T2DM reported a correlation between BMI and levels
of inflammatory proteins and fibrinogen, angiotensinogen and α1-glycoprotein. Here,
the Vd/TBW diminished as the pro-inflammatory cytokine TNF-α increased in the TB–
T2DM patients. One of the systemic effects of this cytokine is the induction of cachexia
(39). It is possible that this situation could lead to a limitation in the distribution of
RIF to other tissues in patients with T2DM. Additionally, this effect is facilitated by a
decrease in blood volume because these patients have little water reabsorption in the
kidney (40).

For the TB-T2DM patients, higher HbA1c correlated with increased tlag, and fasting
glycemia was associated with a negative trend for Cmax. Drug binding to albumin and
α1-glycoprotein may be reduced in the presence of poor glycemic control, possibly
due to the glycosylation of plasma and/or displacement of the drug from the large
amount of free fatty acids due to the lack of metabolic control proteins (38, 41). Otherwise, T2DM may damage the hepatic metabolism of certain drugs, although the mechanisms involved are unknown. Regardless, nearly complete drug removal was observed at 24 hours post-dose because the plasma concentrations were undetectable at the time of sampling.

Chigutsa et al. (13) recently demonstrated that an AUC >35.4 mg·h/L significantly improved the sterilizing activity of RIF. This value was not achieved by two T2DM-TB patients at the beginning of the DOTS scheme; both patients had poor glycemic control (HbA1c >8%), and as expected the Cmax was below the threshold (8.2 mg/L) proposed by the same study. Although the mean AUC values did not significantly differ between groups, the threshold value and the Cmax should be considered individually after at least one week of treatment, as mentioned above. The results of Chigutsa et al., suggested that the sterilizing effect could be increased by dosing RIF and could be applied to design shorter treatments. Previous results with diabetic patients and the results of the current study (10, 11) demonstrate the necessity of improving the glycemic control of TB-T2DM patients at the initiation of the DOTS scheme to achieve the desired threshold values and maintain them throughout the course of treatment.

The half-life of elimination (t1/2) is usually reported to be approximately 2 hours after 2 weeks of treatment (10). Differences in the t1/2 and other RIF pharmacokinetic parameters in Mexican patients were observed but should be interpreted with caution because the sampling schedule was performed on the first day of the DOTS scheme.
This is in contrast to previously published studies, where limited sampling strategies were applied during different TB treatment phases. Diabetes mellitus may impair the hepatic metabolism of some drugs. Although the mechanisms underlying this effect are uncertain, they may reflect liver changes depending on the degree of glycemic control (42). In the current work, RIF’s CL was shown to be lower for TB-T2DM patients compared with TB patients. However, the effect of T2DM on hepatic metabolism most likely does not have major clinical significance in the presence of reasonable glycemic control (38).

In conclusion, in the current study, we characterized metabolic, immune and RIF pharmacokinetic parameters in TB–T2DM patients. The differences in these parameters in the absence of one or both diseases were also established. Data related to metabolic syndrome in T2DM patients were reversed in the TB–T2DM patients. CD8+ T lymphocytes and NK cells were diminished in both the TB and TB–T2DM patients, who exhibited high concentrations of TNF-α but low levels of IL-17. Poor glycemic control without dyslipidemia accompanied by malnutrition was detected in most of the TB–T2DM patients; this was clearly related to the poor and slow absorption of RIF in terms of the lower Cmax and larger tlag, respectively. RIF clearance was also slower in the diabetic patients, thereby prolonging the MRT of the drug. These metabolic and immunologic alterations affecting RIF’s pharmacokinetics should be taken into consideration when optimizing anti-TB therapy for patients with T2DM.
Acknowledgments

The authors would like to acknowledge the support given by the Technological Research Council of Science and Technology (CONACYT) through the subsidy FMSLP-2008-C02-107406. S.E. Medellín-Garibay received a scholarship (309952) from CONACYT for the development of the current study.

Conflict of interest

The authors declare that they have no conflict of interest.
References

   Geneva 27, Switzerland.

   biological determinants of tuberculosis. The international journal of
   tuberculosis and lung disease: the official journal of the International Union
   against Tuberculosis and Lung Disease 15 Suppl 2:S64-70.

   tuberculosis: a systematic review of 13 observational studies. PLoS medicine
   5:e152.

4. Duangrithi D, Thanachartwet V, Desakorn V, Jitruckthai P, Phojanamongkolkij K,
   outcomes of newly diagnosed pulmonary tuberculosis patients in Thailand.

5. Kapur A, Harries AD. 2013. The double burden of diabetes and tuberculosis -

   Goonesekera SD, Murray MB. 2011. The impact of diabetes on tuberculosis
   treatment outcomes: a systematic review. BMC medicine 9:81.

7. O’Garra A, Redford PS, McNab FW, Bloom CI, Wilkinson RJ, Berry MP.
   2013. The immune response in tuberculosis. Annual review of immunology
   31:475-527.


pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis. Antimicrobial agents and chemotherapy 59:38-45.


Brazilian journal of infectious diseases: an official publication of the Brazilian Society of Infectious Diseases 10:374-379.


FIGURE LEGENDS

**Figure 1.** Flow cytometry subpopulations of CD4+ (a) CD8+ (b) T lymphocytes, NK cells (c) and monocytes (d) in peripheral blood mononuclear cells (PBMC) from healthy volunteers and patients with T2DM without evidence of infection and patients with TB and TB–T2DM prior to the initiation of the DOTS scheme. The data represent the mean and standard deviation, and the asterisks indicate significance as follows: *P < 0.05, **P < 0.001 or ***P <0.0001 between groups using ANOVA and the post-hoc tests.

**Figure 2.** Serum TNF-α (a), IFN-γ (b), IL-10 (c), and IL-17 (d) cytokine levels determined using ELISA in healthy volunteers, patients with T2DM without evidence of infection or previous exposure to TB, and TB–T2DM patients at the baseline of the DOTS scheme. The data represent the mean and standard deviation, and the asterisks indicate significance as follows: *P < 0.05 or ***P <0.0001 between groups by ANOVA and the post-hoc tests.

**Figure 3.** Average pharmacokinetic profiles (± standard error) of RIF in healthy volunteers, TB and TB–T2DM patients obtained after a single oral dose administration of a fixed dose combination formulation quantified by HPLC.

**Figure 4.** Correlation between pharmacokinetic parameters obtained after RIF oral administration with glycemic control and pro-inflammatory cytokine production in TB–T2DM patients. Plots show the relationship between: a) lag time in RIF absorption against the glycemic control represented as Hba1c (%); b) maximal concentration of
RIF against fast glycemia; and c) volume of distribution of RIF normalized by total body weight against the serum concentration of TNF-α. A Pearson correlation was performed for each pair; the tendency line, correlation coefficient (r) and significance (P) are shown for each plot. P <0.05 was considered significant.
### Table 1. Anthropometric data and biochemical measurements in patients and healthy volunteers.

<table>
<thead>
<tr>
<th></th>
<th>Healthy volunteers</th>
<th>T2DM patients</th>
<th>TB patients</th>
<th>TB–T2DM patients</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>N (F/M)</td>
<td>24 (15/9)</td>
<td>18 (9/9)</td>
<td>24 (11/13)</td>
<td>24 (11/13)</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>Age (years)</td>
<td>35.8 ± 6.6</td>
<td>45.4 ± 11.4</td>
<td>37.3 ± 14.8</td>
<td>52.2 ± 9.6</td>
<td>&lt;0.001c,f</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>23.7 ± 3.1</td>
<td>32.0 ± 7.5</td>
<td>21.6 ± 3.9</td>
<td>23.3 ± 3.8</td>
<td>&lt;0.0001a,d,e</td>
</tr>
<tr>
<td>Glucose (mg/dL)</td>
<td>79.8 ± 8.3</td>
<td>178 ± 93</td>
<td>88.5 ± 10.8</td>
<td>188 ± 112</td>
<td>&lt;0.0001a,c,d,f</td>
</tr>
<tr>
<td>HbA1c (%)</td>
<td>5.40 ± 0.3</td>
<td>8.27 ± 2.0</td>
<td>5.47 ± 0.7</td>
<td>9.02 ± 2.5</td>
<td>&lt;0.0001a,c,d,f</td>
</tr>
<tr>
<td>Cholesterol (mg/dL)</td>
<td>160 ± 28</td>
<td>188 ± 30</td>
<td>135 ± 26</td>
<td>157 ± 50</td>
<td>0.0001d,e</td>
</tr>
<tr>
<td>Cholesterol HDL (mg/dL)</td>
<td>60.0 ± 12.7</td>
<td>54.9 ± 17.8</td>
<td>41.1 ± 15.6</td>
<td>41.6 ± 15.0</td>
<td>&lt;0.0001a,b,d,e</td>
</tr>
<tr>
<td>Cholesterol LDL (mg/dL)</td>
<td>80.0 ± 22.8</td>
<td>96.2 ± 23.3</td>
<td>69.3 ± 21.2</td>
<td>85.6 ± 36.0</td>
<td>0.014d</td>
</tr>
<tr>
<td>Triglycerides (mg/dL)</td>
<td>98 ± 58</td>
<td>182 ± 71</td>
<td>115 ± 50</td>
<td>148 ± 80</td>
<td>&lt;0.0001a,c,d</td>
</tr>
</tbody>
</table>

Data shown as median ± standard deviation; BMI = body mass index. Bold numbers are statistically significant (P < 0.05); the differences in post-hoc analysis are given between:

- aHealthy volunteers vs. T2DM patients
- bHealthy volunteers vs. TB patients
- cHealthy volunteers vs. TB–T2DM patients
- dT2DM vs. TB patients
- eT2DM vs. TB-T2DM patients
- fTB vs. TB-T2DM patients
Table 2. Pharmacokinetic parameters obtained for RIF in healthy volunteers, patients with TB and TB-T2DM determined from non-compartmental pharmacokinetics and the one-compartment open model after oral administration of a single dose of RIF.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Healthy volunteers</th>
<th>TB patients</th>
<th>TB-T2DM patients</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Dose (mg/kg)</strong></td>
<td>9.41 ± 1.5</td>
<td>10.18 ± 1.7</td>
<td>9.72 ± 1.9</td>
<td>0.23</td>
</tr>
<tr>
<td><strong>Non-compartmental pharmacokinetics</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cmax (mg/L)</td>
<td>13.07 ± 4.5</td>
<td>11.41 ± 3.8</td>
<td>12.10 ± 5.1</td>
<td>0.44</td>
</tr>
<tr>
<td>Tmax (h)</td>
<td>1.84 ± 0.9</td>
<td>2.32 ± 1.4</td>
<td>2.98 ± 1.9</td>
<td>0.03c</td>
</tr>
<tr>
<td>AUC₂₄₀ (mg·h·L⁻¹)</td>
<td>85.29 ± 27.1</td>
<td>82.60 ± 35.5</td>
<td>97.52 ± 36.7</td>
<td>0.17</td>
</tr>
<tr>
<td>AUCₘₘ (_, (mg·h·L⁻¹)</td>
<td>87.53 ± 27.2</td>
<td>87.07 ± 39.9</td>
<td>107.73 ± 56.3</td>
<td>0.18</td>
</tr>
<tr>
<td>MRT (h)</td>
<td>6.34 ± 1.5</td>
<td>7.67 ± 2.7</td>
<td>9.07 ± 5.0</td>
<td>0.02b</td>
</tr>
<tr>
<td><strong>One-compartment open model</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ka (h⁻¹)</td>
<td>3.4 (1.3–8.5)</td>
<td>1.79 (0.8–2.8)</td>
<td>1.80 (0.4–3.4)</td>
<td>0.01abc</td>
</tr>
<tr>
<td>t₁/₂ (h)</td>
<td>0.20 (0.1–0.5)</td>
<td>0.39 (0.2–0.9)</td>
<td>0.39 (0.2–1.8)</td>
<td>0.01abc</td>
</tr>
<tr>
<td>tlag (h)</td>
<td>0.34 ± 0.2</td>
<td>0.51 ± 0.4</td>
<td>0.65 ± 0.4</td>
<td>0.04b</td>
</tr>
<tr>
<td>Vd (L)</td>
<td>36.40 (29.6–45.8)</td>
<td>45.19 (31.3–56.8)</td>
<td>35.40 (28.3–44.4)</td>
<td>0.13</td>
</tr>
<tr>
<td>Vd/TBW (L/kg)</td>
<td>0.651 ± 0.23</td>
<td>0.840 ± 0.31</td>
<td>0.632 ± 0.21</td>
<td>0.01abc</td>
</tr>
<tr>
<td>Ke (h⁻¹)</td>
<td>0.181 ± 0.06</td>
<td>0.208 ± 0.10</td>
<td>0.193 ± 0.08</td>
<td>0.58</td>
</tr>
<tr>
<td>t₁/₀₂ (h)</td>
<td>4.84 ± 1.2</td>
<td>4.31 ± 1.7</td>
<td>3.97 ± 1.5</td>
<td>0.48</td>
</tr>
<tr>
<td>CL (L/h)</td>
<td>7.73 ± 3.2</td>
<td>8.62 ± 3.9</td>
<td>6.04 ± 1.8</td>
<td>0.04c</td>
</tr>
</tbody>
</table>

Bold numbers are statistically significant (P < 0.05); the differences in post-hoc analysis are given between: aHealthy volunteers vs. TB patients; bHealthy volunteers vs. TB–T2DM patients; cTB–T2DM vs. TB patients.
Figure 1.

(a) Lymphocytes CD4+ (cell/μL)

(b) Lymphocytes CD8+ (cell/μL)

(c) NK cells (cell/μL)

(d) Monocytes (cell/μL)

- Healthy volunteers
- TB patients
- TB-T2DM patients
- T2DM patients
Figure 4.